Mary Rinella to Chenodeoxycholic Acid
This is a "connection" page, showing publications Mary Rinella has written about Chenodeoxycholic Acid.
Connection Strength
1.400
-
Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol. 2022 03; 76(3):536-548.
Score: 0.726
-
Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis. J Hepatol. 2023 Nov; 79(5):1110-1120.
Score: 0.204
-
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019 12 14; 394(10215):2184-2196.
Score: 0.159
-
REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. Contemp Clin Trials. 2019 09; 84:105803.
Score: 0.154
-
NAFLD in 2014: Genetics, diagnostics and therapeutic advances in NAFLD. Nat Rev Gastroenterol Hepatol. 2015 Feb; 12(2):65-6.
Score: 0.113
-
Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. Clin Gastroenterol Hepatol. 2022 09; 20(9):2050-2058.e12.
Score: 0.044